Skip to content
Press Releases
Filter Releases
 
Press Releases
Apr 16, 2012
Cambridge, Mass. and South San Francisco, Calif. --- Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), and Veracyte, Inc., a molecular diagnos...
PDF
Apr 5, 2012
South San Francisco, Calif. --- April 5, 2012 --- Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, today announced the appointment of Richard T. Kloos, MD, as Senior Medical Director. In this role, Dr. Kloos will educate the endocrinology community about ...
PDF
Jan 20, 2012
Cambridge, Mass. and South San Francisco, Calif. --- January 20, 2012 --- Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY) and one of the world’s leading biotechnology companies, and Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, today anno...
PDF
Jan 9, 2012
South San Francisco, Calif. --- January 9, 2012 --- Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, today announced that Palmetto GBA, a national contractor that administers Medicare benefits, has established coverage for the company’s Afirma® Gene Expression Classifier f...
PDF
Sep 1, 2011
South San Francisco, Calif. --- September 1, 2011 --- Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, today announced that new data from researchers at Johns Hopkins University School of Medicine suggest that routine use of its Afirma® Gene Expression Classifier for clarifyin...
PDF
Sep 15, 2010
South San Francisco, Calif.--- PRNewswire ---Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, announced that initial data from its large-scale, prospective, multi-center clinical trial were presented today at the 14th International Thyroid Congress, held in Paris, France. The findings showed th...
PDF
Jun 9, 2010
SOUTH SAN FRANCISCO, Calif.--- BUSINESS WIRE ---Veracyte, Inc. announced today the successful completion of its Series B round, a key milestone toward the company’s first product launch later this year. The South San Francisco biotechnology company is committed to pioneering molecular cytology diagnostics to improve patient care and lower ...
PDF
Page: First Previous
...